Innate Pharma S.A. (IPH.PA)
EUR 1.98
(-3.37%)
EUR 1.98
(-3.37%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -7.57 Million EUR | -151.3% |
| 2022 | -61.29 Million EUR | 191.51% |
| 2021 | -43.22 Million EUR | -185.57% |
| 2020 | 43.1 Million EUR | 585.25% |
| 2019 | -20.86 Million EUR | -171.85% |
| 2018 | -3.3 Million EUR | 134.68% |
| 2017 | -35.64 Million EUR | -406.16% |
| 2016 | 10.83 Million EUR | 243.93% |
| 2015 | -8.09 Million EUR | 54.67% |
| 2014 | -17.13 Million EUR | -708.7% |
| 2013 | -1.91 Million EUR | 22.99% |
| 2012 | -1.76 Million EUR | 48.27% |
| 2011 | -5.8 Million EUR | 56.0% |
| 2010 | -12.32 Million EUR | 12.97% |
| 2009 | -14.46 Million EUR | -38.21% |
| 2008 | -12.47 Million EUR | -23.08% |
| 2007 | -8.5 Million EUR | -49.38% |
| 2006 | -6.94 Million EUR | 2.32% |
| 2005 | -6.11 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -12.78 Million EUR | -145.89% |
| 2024 Q2 | -12.78 Million EUR | 0.0% |
| 2023 Q4 | -5.19 Million EUR | 0.0% |
| 2023 Q3 | -5.19 Million EUR | -223.26% |
| 2023 Q1 | 1.4 Million EUR | 105.33% |
| 2023 FY | - EUR | -151.3% |
| 2023 Q2 | -1.6 Million EUR | -214.12% |
| 2022 FY | - EUR | 191.51% |
| 2022 Q1 | 4.99 Million EUR | 117.51% |
| 2022 Q2 | 6.21 Million EUR | 24.48% |
| 2022 Q3 | -11 Million EUR | -277.01% |
| 2022 Q4 | -26.42 Million EUR | -140.1% |
| 2021 Q1 | -9.45 Million EUR | 12.86% |
| 2021 FY | - EUR | -185.57% |
| 2021 Q3 | -12.16 Million EUR | 50.13% |
| 2021 Q2 | -24.38 Million EUR | -157.98% |
| 2021 Q4 | -28.52 Million EUR | -134.54% |
| 2020 FY | - EUR | 585.25% |
| 2020 Q1 | -814.5 Thousand EUR | 97.43% |
| 2020 Q4 | -10.84 Million EUR | -322.59% |
| 2020 Q3 | -2.56 Million EUR | 72.78% |
| 2020 Q2 | -9.42 Million EUR | -1057.64% |
| 2019 Q2 | 12.53 Million EUR | 53.97% |
| 2019 Q3 | -13.82 Million EUR | -210.32% |
| 2019 Q4 | -31.75 Million EUR | -129.61% |
| 2019 FY | - EUR | -171.85% |
| 2019 Q1 | 8.14 Million EUR | -34.73% |
| 2018 Q1 | -6.23 Million EUR | 36.04% |
| 2018 FY | - EUR | 134.68% |
| 2018 Q4 | 12.47 Million EUR | 0.0% |
| 2018 Q3 | 12.47 Million EUR | 300.16% |
| 2018 Q2 | -6.23 Million EUR | 0.0% |
| 2017 Q1 | -8.05 Million EUR | -232.02% |
| 2017 FY | - EUR | -406.16% |
| 2017 Q4 | -9.74 Million EUR | 0.0% |
| 2017 Q3 | -9.74 Million EUR | -20.99% |
| 2017 Q2 | -8.05 Million EUR | 0.0% |
| 2016 Q2 | -682 Thousand EUR | 0.0% |
| 2016 FY | - EUR | 243.93% |
| 2016 Q4 | 6.09 Million EUR | 0.0% |
| 2016 Q3 | 6.09 Million EUR | 994.28% |
| 2016 Q1 | -682 Thousand EUR | -178.08% |
| 2015 Q1 | -4.93 Million EUR | -2.31% |
| 2015 FY | - EUR | 54.67% |
| 2015 Q2 | -4.93 Million EUR | 0.0% |
| 2015 Q4 | 873.5 Thousand EUR | 0.0% |
| 2015 Q3 | 873.5 Thousand EUR | 117.71% |
| 2014 Q3 | -4.82 Million EUR | -20.83% |
| 2014 Q1 | -3.99 Million EUR | -4765.85% |
| 2014 Q2 | -3.99 Million EUR | 0.0% |
| 2014 Q4 | -4.82 Million EUR | 0.0% |
| 2014 FY | - EUR | -708.7% |
| 2013 Q3 | -82 Thousand EUR | 90.61% |
| 2013 Q1 | -873 Thousand EUR | -126.46% |
| 2013 FY | - EUR | 22.99% |
| 2013 Q4 | -82 Thousand EUR | 0.0% |
| 2013 Q2 | -873 Thousand EUR | 0.0% |
| 2012 Q4 | -385.5 Thousand EUR | 0.0% |
| 2012 FY | - EUR | 48.27% |
| 2012 Q3 | -385.5 Thousand EUR | 0.0% |
| 2011 FY | - EUR | 56.0% |
| 2010 FY | - EUR | 12.97% |
| 2009 FY | - EUR | -38.21% |
| 2008 FY | - EUR | -23.08% |
| 2007 FY | - EUR | -49.38% |
| 2006 FY | - EUR | 2.32% |
| 2005 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.29 Million EUR | -130.334% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 94.311% |
| Adocia SA | -22.73 Million EUR | 66.664% |
| Aelis Farma SA | -6.34 Million EUR | -19.395% |
| Biophytis S.A. | -13.8 Million EUR | 45.103% |
| Advicenne S.A. | -6.24 Million EUR | -21.365% |
| genOway Société anonyme | 6.35 Million EUR | 219.324% |
| IntegraGen SA | -52.5 Thousand EUR | -14333.461% |
| Medesis Pharma S.A. | -3.84 Million EUR | -97.093% |
| Neovacs S.A. | -8.44 Million EUR | 10.315% |
| NFL Biosciences SA | -4.04 Million EUR | -87.143% |
| Plant Advanced Technologies SA | 72.53 Thousand EUR | 10548.09% |
| Quantum Genomics Société Anonyme | -2.87 Million EUR | -163.722% |
| Sensorion SA | -22.31 Million EUR | 66.039% |
| Theranexus Société Anonyme | -7.38 Million EUR | -2.582% |
| TME Pharma N.V. | -5.07 Million EUR | -49.409% |
| Valbiotis SA | -6.95 Million EUR | -8.958% |
| TheraVet SA | -517.33 Thousand EUR | -1364.812% |
| Valerio Therapeutics Société anonyme | -18.91 Million EUR | 59.939% |
| argenx SE | -199.5 Million EUR | 96.202% |
| BioSenic S.A. | -6.79 Million EUR | -11.507% |
| Celyad Oncology SA | -7.76 Million EUR | 2.383% |
| DBV Technologies S.A. | -79.53 Million EUR | 90.472% |
| Galapagos NV | 51.03 Million EUR | 114.848% |
| Genfit S.A. | -28.05 Million EUR | 72.985% |
| GeNeuro SA | -14.31 Million EUR | 47.073% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | 49.413% |
| Inventiva S.A. | -101.84 Million EUR | 92.56% |
| MaaT Pharma SA | -19.74 Million EUR | 61.611% |
| MedinCell S.A. | -20.04 Million EUR | 62.197% |
| Nanobiotix S.A. | -34.01 Million EUR | 77.724% |
| Onward Medical N.V. | -35.23 Million EUR | 78.492% |
| Oryzon Genomics S.A. | -4.43 Million EUR | -70.931% |
| OSE Immunotherapeutics SA | -23.26 Million EUR | 67.429% |
| Oxurion NV | -16.72 Million EUR | 54.701% |
| Pharming Group N.V. | 4.98 Million EUR | 252.139% |
| Poxel S.A. | -12.17 Million EUR | 37.778% |
| GenSight Biologics S.A. | -21.73 Million EUR | 65.127% |
| Transgene SA | -27.02 Million EUR | 71.958% |
| Financière de Tubize SA | 184.57 Thousand EUR | 4205.737% |
| UCB SA | 1.26 Billion EUR | 100.597% |
| Valneva SE | -64.51 Million EUR | 88.254% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | 73.273% |